1. Identify the most pertinent emerging therapeutics in lymphoma and multiple myeloma and implement practice-changing data into their clinical practice.

2. Summarize the benefits and limitations of CAR-T transplantation for patients with relapsed multiple myeloma

3. Explain the differences between LOXO-305 and the currently available BTK inhibitors

4. Identify CAR-T options with promising clinical trial data versus already FDA approved for lymphoma

5. Outline the current available evidence for CNS relapse in DLBCL

 

Event address for attendees: https://uwmadison.webex.com/uwmadison/onstage/g.php?MTID=eaef33b9897f676cd1f88bc3551ccf887

Session date: 
Wednesday, January 6, 2021 - 8:00am to 9:00am
Location: 
Clinical Science Center, G5/119
600 Highland Ave
Madison, WI 53792
United States
  • 1.00 ACPE Contact Hours - Pharmacist
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC Contact Hours
  • 1.00 University of Wisconsin–Madison Continuing Education Hours

Please login or register to take this course.
Discloser List CME Internal Report
Presenter(s): 
Dr. Vaishalee Kenkre
Dr. Saurabh Rajguru
Dr. Priyanka Pophali
Dr. Tim Schmidt
Dr. Natalie Callander